Antineoplastic drug-induced bradyarrhythmias

Bibliography

• Guglin M, Aljayeh M, Saiyad S, Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009;11:1579-86
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47
   PubMed Web of Science ®Google Scholar
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11
   PubMed Web of Science ®Google Scholar
• Dreifus LS, Michelson EL, Kaplinsky E. Bradyarrhythmias: clinical significance and management. J Am Coll Cardiol 1983;1:327-38
   PubMed Web of Science ®Google Scholar
• Mordente A, Meucci E, Silvestrini A, New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009;16:1656-72
   PubMed Web of Science ®Google Scholar
• Binah O, Cohen IS, Rosen MR. The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers. Circ Res 1983;53:655-62
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62
   PubMed Web of Science ®Google Scholar
• Kilickap S, Akgul E, Aksoy S, Doxorubicin-induced second degree and complete atrioventricular block. Europace 2005;7:227-30
   PubMed Web of Science ®Google Scholar
• Kilickap S, Barista I, Akgul E, Early and late arrhythmogenic effects of doxorubicin. South Med J 2007;100:262-5
   PubMed Web of Science ®Google Scholar
• Friess GG, Boyd JF, Geer MR, Garcia JC. Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. Cancer 1985;56:2762-4
   PubMed Web of Science ®Google Scholar
• Umemoto M, Kawasaki H, Azuma E, Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy. Am J Hematol 1996;52:327-8
   PubMed Web of Science ®Google Scholar
• Benekli M, Kars A, Guler N. Mitoxantrone-induced bradycardia. Ann Intern Med 1997;126:409
   PubMed Web of Science ®Google Scholar
• Chan-Tack K. Sinus bradycardia due to mitoxantrone. South Med J 2000;93:440
   PubMed Web of Science ®Google Scholar
• Usnarska-Zubkiewicz L, Sciborski R, Nowosad H, Effect of epirubicin on the heart conduction system in patients with Hodgkin's disease. Pol Arch Med Wewn 1992;87:173-82
   PubMedGoogle Scholar
• Bethell H, Grace AA, Hall JA, Bradycardia due to anthracyclines. Lancet 1992;340:858
   PubMed Web of Science ®Google Scholar
• Horacek JM, Jakl M, Horackova J, Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 2009;31:115-17
   PubMedGoogle Scholar
• Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007;7:67-71
   PubMed Web of Science ®Google Scholar
• Dang C, Fornier M, Sugarman S, The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26:1216-22
   PubMed Web of Science ®Google Scholar
• Tassinari D, Sartori S, Drudi G, Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol 1997;8:1263-7
   PubMed Web of Science ®Google Scholar
• Sculier JP, Coune A, Klastersky J. Transient heart block. An unreported toxicity of high dose chemotherapy with cyclophosphamide and etoposide. Acta Clin Belg 1985;40:112-14
   PubMed Web of Science ®Google Scholar
• Gryn J, Gordon R, Bapat A, Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant 1993;12:217-20
   PubMed Web of Science ®Google Scholar
• Ramireddy K, Kane KM, Adhar GC. Acquired episodic complete heart block after high-dose chemotherapy with cyclophosphamide and thiotepa. Am Heart J 1994;127:701-4
   PubMed Web of Science ®Google Scholar
• Ifran A, Kaptan K, Beyan C. High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am J Hematol 2005;80:246-7
   PubMedGoogle Scholar
• Morandi P, Ruffini PA, Benvenuto GM, Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005;35:323-34
   PubMed Web of Science ®Google Scholar
• Ando M, Yokozawa T, Sawada J, Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2000;25:185-9
   PubMed Web of Science ®Google Scholar
• Zver S, Zadnik V, Bunc M, Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007;85:408-14
   PubMed Web of Science ®Google Scholar
• Zver S, Zadnik V, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008;88:227-36
   PubMed Web of Science ®Google Scholar
• Yeh ET, Tong AT, Lenihan DJ, Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31
   PubMed Web of Science ®Google Scholar
• Schlaeffer F, Tovi F, Leiberman A. Cisplatin-induced bradycardia. Drug Intell Clin Pharm 1983;17:899-901
   PubMedGoogle Scholar
• Altundag O, Celik I, Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother 2001;35:641-2
   PubMed Web of Science ®Google Scholar
• Ekholm EM, Salminen EK, Huikuri HV, Impairment of heart rate variability during paclitaxel therapy. Cancer 2000;88:2149-53
   PubMed Web of Science ®Google Scholar
• Alloatti G, Penna C, Gallo MP, Differential effects of paclitaxel and derivatives on guinea pig isolated heart and papillary muscle. J Pharmacol Exp Ther 1998;284:561-7
   PubMed Web of Science ®Google Scholar
• Boehmerle W, Splittgerber U, Lazarus MB, Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci USA 2006;103:18356-61
   PubMed Web of Science ®Google Scholar
• Zhang K, Heidrich FM, DeGray B, Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R. J Mol Cell Cardiol 2010;49:829-35
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Strauss H, Rowinsky E, A reassessment of cardiac toxicity associated with Taxol. J. Natl Cancer Inst Monogr 1993;15:117-30
   PubMedGoogle Scholar
• Rowinsky EK, Eisenhauer EA, Chaudhry V, Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;4:1-15
   Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12
   PubMed Web of Science ®Google Scholar
• Kietpeerakool C, Tiyayon J, Suprasert P, Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer. J Med Assoc Thai 2006;89:1805-10
   PubMedGoogle Scholar
• Zekri JM. Case report and review of literature: temporary asymptomatic sinus bradycardia with carboplatin, paclitaxel and bevacizumab: under-reported in clinical trials and under-disclosed in practice. Gulf J Oncol 2011;1:60-4
   Google Scholar
• Ekholm E, Rantanen V, Syvanen K, Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines. Anticancer Drugs 2002;13:425-9
   PubMed Web of Science ®Google Scholar
• Palma M, Mancuso A, Grifalchi F, Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002;88:527-9
   PubMed Web of Science ®Google Scholar
• Salminen E, Syvanen K, Korpela J, Docetaxel with epirubicin–investigations on cardiac safety. Anticancer Drugs 2003;14:73-7
   PubMed Web of Science ®Google Scholar
• Sanborn SL, Cooney MM, Dowlati A, Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 2008;26:355-62
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta G, Clerici M, Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68:505-10
   PubMed Web of Science ®Google Scholar
• de Forni M, Malet-Martino MC, Jaillais P, Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795-801
   PubMed Web of Science ®Google Scholar
• Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993;50:441-4
   PubMed Web of Science ®Google Scholar
• Meyer CC, Calis KA, Burke LB, Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17:729-36
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009;8:191-202
   PubMed Web of Science ®Google Scholar
• Molteni LP, Rampinelli I, Cergnul M, Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 2010;16:S45-8
   Google Scholar
• Tsibiribi P, Bui–Xuan C, Bui–Xuan B, Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006;25:305-9
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kallistratos MS, Kopterides P, Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75-82
   PubMed Web of Science ®Google Scholar
• Levillain R. Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluorouracil. C R Seances Soc Biol Fil 1972;166:340-2
   PubMedGoogle Scholar
• Stevenson DL, Mikhailidis DP, Gillett DS. Cardiotoxicity of 5-fluorouracil. Lancet 1977;2:406-7
   PubMed Web of Science ®Google Scholar
• Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol 2010;17:59-63
   PubMed Web of Science ®Google Scholar
• Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010;40:303-7
   PubMed Web of Science ®Google Scholar
• Talapatra K, Rajesh I, Rajesh B, Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Can Res Ther 2007;3:169-71
   PubMedGoogle Scholar
• Lee AD, McKay MJ. Symptomatic 5-fluorouracil-induced sinus bradycardia. Intern Med J 2011;41:566-70
   PubMed Web of Science ®Google Scholar
• Tunio MA, Hashmi A, Shoaib M. Capecitabine induced cardiotoxicity: a case report and review of literature. Pak J Pharm Sci 2012;25:277-81
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Kanellopoulou G, Vaiopoulos G, Evidence for sinoatrial blockade associated with high dose cytarabine therapy. Leuk Res 1998;22:759-61
   PubMed Web of Science ®Google Scholar
• Backway KL, McCulloch EA, Chow S, Hedley DW. Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res 1997;57:2446-51
   PubMed Web of Science ®Google Scholar
• Kumagawa M, Suzuki K, Nagano M, High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22). Rinsho Ketsueki 2003;44:404-6
   PubMedGoogle Scholar
• Cil T, Kaplan MA, Altintas A, Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report. Leuk Lymphoma 2007;48:1247-9
   PubMed Web of Science ®Google Scholar
• Romani C, Pettinau M, Murru R, Angelucci E. Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution. Eur J Cancer Care 2009;18:320-1
   PubMed Web of Science ®Google Scholar
• Chung-Lo W, Hsieh CY, Chiu CF, Bai LY. Fludarabine-induced bradycardia in a patient with refractory leukemia. Ann Saudi Med 2010;30:246-7
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001;15:163-72
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15
   PubMed Web of Science ®Google Scholar
• Palumbo A, Facon T, Sonneveld P, Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968-77
   PubMed Web of Science ®Google Scholar
• Bovelli D, Plataniotis G, Roila F; ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010;21:277-82
   PubMed Web of Science ®Google Scholar
• Fahdi IE, Gaddam V, Saucedo JF, Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 2004;93:1052-5
   PubMed Web of Science ®Google Scholar
• Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001;24:87-117
   PubMed Web of Science ®Google Scholar
• Kneller A, Raanani P, Hardan I, Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000;108:391-3
   PubMed Web of Science ®Google Scholar
• Juliusson G, Celsing F, Turesson I, Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96
   PubMed Web of Science ®Google Scholar
• Hus M, Dmoszynska A, Soroka-Wojtaszko M, Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86:404-8
   PubMed Web of Science ®Google Scholar
• Coutsouvelis J, Corallo CE. Thalidomide-induced bradycardia and its management. Med J Aust 2004;180:366-7
   PubMed Web of Science ®Google Scholar
• Amato RJ, Sarao H. A phase I study of paclitaxel/doxorubicin/thalidomide in patients with androgen- independent prostate cancer. Clin Genitourin Cancer 2006;4:281-6
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30
   PubMed Web of Science ®Google Scholar
• Lopez-de la Cruz I, Aguayo-Gonzalez A, Lopez-Karpovitch X. Thalidomide-associated bradycardia in patients with hematologic diseases: a single institution experience. Rev Invest Clin 2006;58:424-31
   PubMed Web of Science ®Google Scholar
• Hinterseer M, Becker A, Kaab S, Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol 2006;95:474-6
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-19
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Marcolino MS, Bittencourt HN, An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 2008;32:1809-14
   PubMed Web of Science ®Google Scholar
• Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964-70
   PubMed Web of Science ®Google Scholar
• Bello CL, Mulay M, Huang X, Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009;15:7045-52
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol 2005;1:161-71
   PubMedGoogle Scholar
• Yu X, Huang S, Patterson E, Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol 2005;289:H1960-7
   PubMed Web of Science ®Google Scholar
• Berenson JR, Jagannath S, Barlogie B, Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141-8
   PubMed Web of Science ®Google Scholar
• Jancso G, Cserepes B, Gasz B, Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. J Cardiovasc Pharmacol 2005;46:295-301
   PubMed Web of Science ®Google Scholar
• Enrico O, Gabriele B, Nadia C, Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138:396-7
   PubMed Web of Science ®Google Scholar
• Nowis D, Maczewski M, Mackiewicz U, Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658-68
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract 2011;17:282-4
   PubMedGoogle Scholar
• Lee WS, Kim DH, Shin SH, Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J 2011;52:196-8
   PubMed Web of Science ®Google Scholar
• Kilickap S, Yavuz B, Aksoy S, Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol 2008;25:437-42
   PubMed Web of Science ®Google Scholar
• Cervera Grau JM, Esquerdo Galiana G, Belso Candela A, Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin's diffuse large B-cell lymphoma. Clin Transl Oncol 2008;10:298-9
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25
   PubMed Web of Science ®Google Scholar
• Kaur A, Yu SS, Lee AJ, Chiao TB. Thalidomide-induced sinus bradycardia. Ann Pharmacother 2003;37:1040-3
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Semin Hematol 2003;40:17-22
   PubMed Web of Science ®Google Scholar